Stocktoria
Fresenius SE & Co. KGaA FRE.DE
DE · Deutsche Börse Xetra · XETR · stock · Healthcare · website
Fresenius SE & Co. KGaA financials (annual)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | €22.9B | €22.0B | €21.1B | €21.5B |
| Gross profit | €5.7B | €5.6B | €5.0B | €5.4B |
| R&D expense | €633.0M | €641.0M | €661.0M | €639.0M |
| SG&A expense | €2.9B | €2.9B | €3.0B | €3.1B |
| Operating income | €2.2B | €2.1B | €1.2B | €1.8B |
| Interest expense | €445.0M | €552.0M | €519.0M | €345.0M |
| Income tax | €582.0M | €530.0M | €485.0M | €375.0M |
| Net income | €1.3B | €471.0M | -€594.0M | €1.4B |
| EPS (diluted) | €2.24 | €0.84 | €-1.05 | €2.44 |
| Operating cash flow | €2.6B | €2.4B | €4.5B | €4.2B |
| Free cash flow | €1.1B | €1.4B | €3.2B | €3.0B |
| Cash & equivalents | €1.3B | €2.0B | €2.3B | €2.6B |
| Inventory | €2.6B | €2.6B | €2.5B | €4.8B |
| Goodwill | €14.5B | €15.1B | €15.1B | €31.5B |
| Total assets | €41.4B | €43.5B | €45.3B | €76.4B |
| Total debt | €11.9B | €13.6B | €15.8B | €27.8B |
| Total liabilities | €21.6B | €23.3B | €25.6B | €44.2B |
| Shareholders' equity | €19.1B | €19.5B | €19.0B | €20.4B |
Growth · year-over-year · Revenue CAGR 2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | +4.2% | +4.2% | -2.2% | — |
| Net income growth | +168.4% | — | -143.3% | — |
| EPS growth | +166.7% | — | -143.0% | — |
| Free cash flow growth | -22.4% | -56.2% | +5.5% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · DE · as of 2025-12-31. Figures in EUR. Facts plus Stocktoria's own computed scores — not investment advice.